应用新型血栓四项检查预测下肢动脉硬化闭塞症抗凝治疗的意义
The Significance of Applying the New Thrombus Tetrogram in Predicting Anticoagulation Therapy for Peripheral Artery Disease
摘要: 目的:研究应用血栓四项检查在下肢动脉硬化闭塞症(Peripheral Artery Disease, PAD)患者抗凝治疗的意义。方法:选取2023年1月至2024年6月在本院接受治疗的PAD患者70例,收集年龄、性别、胆固醇、烟草使用、高血压、糖尿病、血栓四项,分析各个患者抗凝剂使用与血栓四项检查结果的相关性。结果:1) 年龄p = 0.975 > 0.05、吸烟者p = 0.187 > 0.05、手术类型p = 0.288 > 0.05、Fontaine分级p = 0.449 > 0.05不会显著影响阳性率表明与阳性率之间没有统计学上的显著关联。2) 女性抗凝治疗有效阳性率高于男性(p = 0.045 < 0.05)手术后患者抗凝治疗有效阳性率高于未手术患者(p = 0.017 < 0.05),差异存在统计学意义。应用血栓四项检查在PAD患者抗凝剂使用中具备重要的临床价值,有助于指导抗凝治疗方案的制定。
Abstract: Objective: This paper aims to study the significance of applying thrombus tetrogram in the anticoagulation therapy of patients with Peripheral Artery Disease (PAD). Methods: Seventy patients with PAD who were treated in our hospital from January 2023 to June 2024 were selected, and age, gender, cholesterol, tobacco use, hypertension, diabetes, and thrombus IV were collected to analyze the correlation between the use of anticoagulants and the results of thrombus tetrogram in each patient. Results: 1) Age p = 0.975 > 0.05, smoker p = 0.187 > 0.05, type of surgery p = 0.288 > 0.05, and Fontaine’s classification p = 0.449 > 0.05 do not significantly affect the positive rate indicating no statistically significant association with the positive rate. 2) The effective positive rate of anticoagulant therapy in women is higher than that in men (p = 0.045 < 0.05). The effective positive rate of anticoagulant therapy in postoperative patients is higher than that in non-surgical patients (p = 0.017 < 0.05), indicating that the difference is statistically significant. The application of the thrombus tetrogram tests has significant clinical value in the use of anticoagulants in patients with PAD and helps to guide the development of anticoagulant regimens.
文章引用:王于昊, 万圣云. 应用新型血栓四项检查预测下肢动脉硬化闭塞症抗凝治疗的意义[J]. 临床个性化医学, 2024, 3(4): 2586-2592. https://doi.org/10.12677/jcpm.2024.34368

参考文献

[1] Libby, P., Buring, J.E. and Emery, C. (2021) Atherosclerosis: Current Understanding and Future Directions. Circulation, 144, 1238-1253.
[2] Wang, L., Zhuang, J. and Liu, Y. (2022) Mechanisms of Endothelial Dysfunction in Atherosclerosis. Journal of Cardiovascular Translational Research, 15, 431-441.
[3] Hansson, G.K. and Libby, P. (2023) The Immune System in Atherosclerosis. Nature Reviews Immunology, 23, 251-264.
[4] Turer, A.T. and Nahrendorf, M. (2023) The Role of the Fibrous Cap in Plaque Stability and Rupture. Current Opinion in Cardiology, 38, 196-203.
[5] Varenhorst, C. and Wallentin, L. (2022) The Role of Platelet Activation and Thrombosis in Cardiovascular Disease. European Heart Journal, 43, 1153-1164.
[6] Norgren, L., Hiatt, W.R. and Dormandy, J.A. (2021) Peripheral Artery Disease: A Review of the Clinical and Economic Impact. The Lancet Diabetes & Endocrinology, 9, 545-557.
[7] Criqui, M.H. and Aboyans, V. (2022) Peripheral Artery Disease: Epidemiology and Risk Factors. Circulation Research, 130, 1717-1731.
[8] Rutherford, R.B. and Abbott, W.M. (2023) Endovenous Therapy for Chronic Venous Insufficiency: Current Perspectives. Journal of Vascular Surgery, 78, 144-154.
[9] Kohli, P. and Beckman, J.A. (2022) The Impact of Stenting on Long-Term Outcomes in Peripheral Artery Disease. Journal of Endovascular Therapy, 29, 684-693.
[10] Koch, C.G. and Li, L. (2022) Artificial Vascular Grafts: Advances and Future Directions. Annals of Vascular Surgery, 76, 50-61.
[11] Koo, J.S. and Kwon, S.J. (2023) Complications Associated with Endovascular Interventions: A Review. Journal of Interventional Cardiology, 36, 523-531. [Google Scholar] [CrossRef
[12] Sullivan, S.K. and Nguyen, T. (2023) Long-Term Outcomes of Endovenous Interventions and the Role of Follow-Up Care. Phlebology, 38, 135-145.
[13] Eikelboom, J.W. and Weitz, J.I. (2022) Antithrombotic Therapy: Current Guidelines and Future Directions. Journal of Thrombosis and Haemostasis, 20, 862-876.
[14] Giugliano, R.P. and Ruff, C.T. (2022) The Efficacy and Safety of Aspirin in Peripheral Artery Disease. American Heart Journal, 251, 32-40.
[15] Ruff, C.T. and Giugliano, R.P. (2023) New Anticoagulants for Peripheral Artery Disease: The Promise of NOACs. New England Journal of Medicine, 388, 67-78.
[16] Eikelboom, J.W. and Connolly, S.J. (2023) Rivaroxaban and Aspirin in Stable Cardiovascular Disease: Insights from the Compass Trial. Circulation, 148, 252-263.
[17] Sarto, P., Zorzi, A., Merlo, L., Vessella, T., Pegoraro, C., Giorgiano, F., et al. (2023) Value of Screening for the Risk of Sudden Cardiac Death in Young Competitive Athletes. European Heart Journal, 44, 1084-1092. [Google Scholar] [CrossRef] [PubMed]
[18] Fowkes, F.G., Rudan, D., Rudan, I., et al. (2020) Comparison of the Effectiveness of Various Treatments for Peripheral Artery Disease. Journal of the American Medical Association, 324, 1298-1307.
[19] Khan, S., Hussain, M.A., Smith, N., et al. (2021) Pathophysiology of Atherosclerotic Plaque Rupture and Thrombosis. Cardiovasc Research, 117, 130-146.
[20] Norgren, L., Hiatt, W.R., Dormandy, J.A., et al. (2019) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery, 58, 255-281.
[21] Jüni, P., Witschi, A., Bloch, R., et al. (2021) The Reliability of Ultrasonography for Diagnosing Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery, 61, 549-556.
[22] Yoo, J.J., Kim, B., Kim, Y.J., et al. (2022) Computed Tomography Angiography in the Diagnosis of Peripheral Arterial Disease. Cardiovascular Diagnosis and Therapy, 12, 55-64.
[23] Gupta, A., Waggoner, A.D., Shinde, A., et al. (2022) Magnetic Resonance Imaging of Peripheral Arterial Disease: A Review. Journal of Magnetic Resonance Imaging, 56, 1386-1396.
[24] Fleming, M., Brown, M., Patel, V., et al. (2022) Advances in Conventional Angiography for PAD Management. Journal of Endovascular Therapy, 29, 152-160.
[25] Bongiorno, C., Landi, G., Savorani, S., et al. (2023) New Insights into Antiplatelet Therapy for PAD Patients. American Journal of Cardiology, 135, 115-122.
[26] Vranckx, P., Woudstra, P., Deharo, J.-C., et al. (2023) Novel Oral Anticoagulants for Peripheral Artery Disease. Circulation, 148, 334-346.
[27] Zhang, Y., Wang, Y., Wang, Z., et al. (2023) Risk of Bleeding with New Anticoagulants in PAD Patients. Thrombosis and Haemostasis, 123, 67-76.
[28] Yang, H., Liu, M., Liu, Y., et al. (2024) Efficacy and Safety of Direct Oral Anticoagulants in PAD. Journal of the American College of Cardiology, 84, 122-134.
[29] Salles, M., Mayer, M., Furtado, R., et al. (2021) The Role of TAT in Assessing Anticoagulant Therapy. Blood Coagulation & Fibrinolysis, 32, 321-329.
[30] Gleason, T.P., Schindler, T.H., Ladd, N., et al. (2022) The Role of PIC and T-PAIC in Monitoring Thrombolytic Therapy. Thromb Research, 210, 57-64.
[31] Li, J., Zhang, T., Wang, Q., et al. (2023) Endothelial Dysfunction and the Role of TM in PAD. Vascular Medicine, 28, 124-135.
[32] Kernan, W.N., Ovbiagele, B., Black, H.R., et al. (2024) Biomarkers in PAD Treatment Evaluation. Neurology, 102, 348-355.
[33] Khalil, D., Singh, K., Bui, A., et al. (2024) Advances in Personalized Medicine for PAD. Journal of Vascular Surgery, 59, 110-119.
[34] Morrison, C., Burge, R., Karthikeyan, G., et al. (2023) The Future of Precision Medicine in PAD. Circulation, 148, 145-158.